Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
| Autor: | Eleni Lagoudaki, Eleftheria-Kleio Dermitzaki, John Souglakos, Athanasios Kotsakis, Vassilis Georgoulias, Eleni Politaki, Anastasios Koutsopoulos, Filippos Koinis, Ippokratis Messaritakis, Galatea Kallergi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Pathology Lung Neoplasms Physiology Immunofluorescence Cancer Treatment lcsh:Medicine Apoptosis Lung and Intrathoracic Tumors Small Cell Lung Cancer 0302 clinical medicine Circulating tumor cell Immunofluorescence Staining Medicine and Health Sciences lcsh:Science Aged 80 and over Staining Multidisciplinary Cell Death medicine.diagnostic_test biology Cell Staining Neoplastic Cells Circulating Phenotype Body Fluids Gene Expression Regulation Neoplastic Phenotypes Blood Oncology Cell Processes 030220 oncology & carcinogenesis Female Non small cell Anatomy Antibody Research Article Adult medicine.medical_specialty Research and Analysis Methods 03 medical and health sciences Cell Line Tumor Genetics medicine Humans Vimentin Clinical significance Immunoassays Aged lcsh:R Cancers and Neoplasms Biology and Life Sciences Cell Biology Small Cell Lung Carcinoma Ki-67 Antigen 030104 developmental biology Specimen Preparation and Treatment Cell culture Leukocytes Mononuclear Immunologic Techniques biology.protein Cancer research lcsh:Q |
| Zdroj: | PLoS ONE, Vol 12, Iss 7, p e0181211 (2017) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Background To evaluate the phenotypic heterogeneity of circulating tumor cells (CTCs) based on the expression of proliferative, apoptotic and Epithelial-to-Mesenchymal Transmission (EMT) markers during front-line treatment in patients with small cell lung cancer (SCLC) and to evaluate their clinical relevance. Methods CTCs from 108 chemotherapy-naive patients with SCLC were analyzed by double immunofluorescence staining using anti-Ki67, anti-M30, anti-Vimentin along with anti-CKs antibodies. In 83 patients CTCs were also enumerated using the CellSearch. Results Sequential samples were available from 76 and 48 patients after one-treatment cycle and on disease progression (PD), respectively, for immunofluorescence and from 50 and 36 patients after one-cycle and on PD, respectively, for CellSearch. At baseline, 60.2% of the patients had detectable CTCs by either method. Both proliferative (CK67+) and non-proliferative (Ki67-), apoptotic (M30+) and non-apoptotic (M30-) as well as EMT (Vim+) CTCs were present in the same patient. Among 22 patients without detectable CTCs by CellSearch, CK+/Ki67+ and CK+/Vim+ CTCs could be detected in 6 (27.3%) and 6 (27.3%) patients, respectively. One-chemotherapy cycle reduced both the incidence of detection (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|